Comparative effectiveness research in chronic obstructive pulmonary disease by Mularski, Richard A et al.
Comparative effectiveness research in chronic obstructive
pulmonary disease
Richard A Mularski1,*, Mary Ann McBurnie1, Peter K Lindenauer2, Todd A Lee3, William M
Vollmer1, David H Au4, Shannon S Carson5, and Jerry A Krishnan3 for the CONCERT
Investigator Consortium
1Kaiser Permanente Center for Health Research, 3800 N. Interstate, Portland, OR 97227, USA
2Baystate Health, Springfield, MA 01199, USA
3University of Illinois at Chicago, Chicago, IL, USA
4University of Washington, Seattle, WA, USA
5University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Abstract
Chronic obstructive pulmonary disease affects millions worldwide. It is America’s third leading
cause of death, and results in significant morbidity and cost. Although many therapies exist and
are being developed to alleviate symptoms and decrease morbidity and mortality in chronic
obstructive pulmonary disease, most have only been studied in placebo-controlled efficacy studies
in highly selected populations. Comparative effectiveness and translational research in chronic
obstructive pulmonary disease will require the development of infrastructures to support
collaboration between researchers and the stakeholders who generate, disseminate and use new
knowledge. Methodologies need to evolve to both prioritize research questions and to conduct
collaborative comparative effectiveness research studies. Given the impracticality of testing every
clinical intervention in comparative pragmatic trials for comparative effectiveness research in
chronic obstructive pulmonary disease, we advocate expanding methodology that includes the use
of observational databases with serially performed effectiveness analyses and quasi-experimental
designs that include following healthcare changes longitudinally over time to assess benefit, harm,
subgroups and cost.
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Chronic obstructive pulmonary disease (COPD) affects 12–24 million people and is a
leading cause of morbidity and mortality in the USA [1,101,102]. COPD recently became
America’s third leading cause of death and results in as many as 800,000 hospital
admissions annually in the USA [102–104]. Approximately one in four patients hospitalized
for COPD are readmitted within 30 days of discharge [2–4,103,104]. Healthcare costs
related to COPD are estimated to be approximately US$32–40 billion each year [5,103,104].
Many therapies exist to decrease symptoms related to COPD, reduce hospitalizations or
exacerbations, and potentially slow disease progression [6–8,105,106]. However, the vast
majority of therapies demonstrated to be beneficial in COPD have been studied in placebo-
controlled efficacy studies in highly selected populations enriched with patients most likely
to benefit, and in research settings in which patients receive intensive support to optimize
self-management and to avoid or minimize medication-related adverse events. Very few
clinical trials have prospectively compared therapeutic alternatives [9,10]. Much of the
comparative research evidence in COPD has been based on observational studies [11,12].
Furthermore, studies in real world populations of COPD that have looked at adoption of
therapies that do have efficacy evidence have found underuse and wide variations in care
delivery across the USA [2,4,13,14]. These considerations highlight the need to identify the
most effective therapies in real world patients with COPD and to design and test efforts to
translate this evidence into healthcare for the millions of patients with COPD. Despite the
potentially large impact on improving the demonstrated deficiencies in the translation of
efficacy research-supported COPD therapies, quality measurement and improvement science
for the treatment and outcomes of patients with COPD has also lagged [15].
In short, there is a need for translational and comparative effectiveness research (CER) in
COPD. We developed a consortium of investigators and stakeholders (COPD Outcomes-
based Network for Clinical Effectiveness and Research Translation [CONCERT]) and
conducted two research development conferences (Setting effectiveness and translational
research priorities to improve COPD care, 21–22 May 2009 in San Diego, CA, USA, and
Setting effectiveness and translational research priorities to improve COPD care, 20–21 May
2010 in New Orleans, LA, USA). In this review, we discuss considerations for CER in
COPD translational research, comment on CER methodology and exemplify some current
CER in COPD.
CER delineated for COPD
US governmental and private sector initiatives have attempted to refocus medical research
on exploring comparisons of clinical strategies in a way that has culminated in the field of
CER. Amongst federal mandates and recent high-profile public discourses, definitions,
priorities and approaches for organizing and conducting CER have emerged. The Institute of
Medicine (IOM), an independent, nonprofit organization that works outside of the US
federal government to provide unbiased and authoritative advice to decision-makers and the
public about health issues as an arm of the National Academy of Sciences, offers a broad
description for CER that includes “the generation and synthesis of evidence that compares
the benefits and harms of alternative methods to prevent, diagnose, treat and monitor a
clinical condition or to improve the delivery of care. The purpose of CER is to assist
consumers, clinicians, purchasers, and policymakers to make informed decisions that will
improve healthcare at both the individual and population levels”[16]. The IOM definition
spans a spectrum from traditional efficacy research through to health services delivery
research to highlight the translation of evidence into practice with an overt goal of
improving the individual and population health. Thus, the IOM has set the stage for health
policy and implementation discourses that include further refinements of the definition.
Mularski et al. Page 2













The Department of Health and Human Services (DHHS), the federal department of the
executive branch of the US government responsible for providing a wide range of health
benefits and services to the American public through programs such as the CDC, the Centers
for Medicare and Medicaid Services (CMS) and the NIH, is the major funder of medical
research in the USA and has been charged under the recent Patient Protection and
Affordable Care Act of 2010 to establish methodological standards for CER and policies for
research funding. The Federal Coordinating Council for Comparative Effectiveness defines
CER as research that “provides information on the relative strengths and weakness of
various medical interventions. Such research will give clinicians and patients valid
information to make decisions that will improve the performance of the USA healthcare
system” [17,18]. And specifically this cross-institute council indicated that CER is the
“conduct and synthesis of research comparing the benefits and harms of different
interventions and strategies to prevent, diagnose, treat and monitor health conditions in ‘real
world’ settings. The purpose of this research is to improve health outcomes by developing
and disseminating evidence-based information to patients, clinicians, and other decision-
makers, responding to their expressed needs, about which interventions are most effective
for which patients under specific circumstances.”
Also established in the 2010 Patient Protection and Affordable Care legislation was the
Patient-Centered Outcomes Research Institute (PCORI), which has been charged with
moving forward from these definitions to establish a functional approach and practical
strategies to develop and organize the infrastructure for prioritizing and conducting CER.
The research questions most appropriate for CER in COPD need to be defined and
prioritized. Given the emphasis in the DHHS definition of CER on end users (patients,
clinicians and other decision-makers), prioritization of CER questions requires input from
the diverse perspectives of stakeholders who generate, disseminate and will hopefully use
new knowledge.
Another US federal branch of the DHHS, the Agency for Healthcare Research and Quality
(AHRQ), focuses on the health delivery end of the research spectrum and proposed steps for
conducting CER with an expressed goal of furthering the development of the research
infrastructure as follows [19,107]:
• Identify new and emerging clinical interventions
• Review and synthesize current medical research
• Identify gaps between existing medical research and the needs of clinical practice
• Promote and generate new scientific evidence and analytic tools
• Train and develop clinical researchers
• Translate and disseminate research findings to diverse stakeholders
• Reach out to stakeholders via a citizens’ forum
Each of the institutes within the NIH, AHRQ and CMS has chosen to focus its funding upon
different aspects of CER infrastructure and research. The NIH as the major funder of basic
science and clinical trials is targeting trial infrastructure such as expanding clinical trial
networks and developing novel requests for applications and other investigator-initiated
grants; the AHRQ continues its focus on review and synthesis of existing evidence while
advancing novel approaches for CER methodology; and the CMS is focusing on
infrastructure and database development through initiatives such as the Multi-Payer
Research Database [17,20]. With multiple branches of the US government emphasizing the
adoption of meaningful use of electronic medical records, it is anticipated that databases
available for CER will expand in the future.
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Characterizations of CER recognize that for this evolving research paradigm to succeed in
improving health across the USA, it must assess a wide range of health-related outcomes
across diverse patient populations and subgroups. This strategy is in contradistinction to
traditional efficacy research that narrowly defines its research population to avoid
contamination by confounds to the major clinical effect under study. The result of a
narrowed population is its compromise to external validity or what has been termed
generalizability; for example, can a physician apply the results of an efficacy study to a
particular patient or patient population. Extensive exclusion and inclusion criteria of efficacy
studies or randomized controlled trials (RCTs) may severely limit generalizability or
application of evidence. Thus, CER strives to conduct research in a more usable way across
broad populations of ‘real world’ patients with the goal that health can be improved.
Moreover, CER suggests that interventions for comparison are equally broad, spanning such
therapies as medications, procedures, medical and assistive devices and technologies,
diagnostic testing, behavioral change and delivery system strategies. In addition, the field of
CER and its champions, such as the IOM and PCORI, are engaged in expanding data
sources and methods of assessment to achieve efficient, impactful studies with active
dissemination of results that can and will be useful in healthcare [18,20–22]. Implicit across
the definitions of CER is the need for novel methodology to include broad stakeholder input
to prioritize research topics and engage in subsequent practical translation. The imperative
that CER “responds to the expressed needs of patients, clinicians, and other decision-
makers” necessitates ways to bring researchers, providers, administrators, patients and
payers together to develop research agendas and apply the generated evidence
[16,17,20,107]. The new networks and institutes, such as the PCORI, have begun to
establish methods groups to identify optimal ways to synthesize and conduct CER.
General methodological approaches for consideration in CER for COPD
CER is concerned with the conduct and synthesis of systematic research comparing different
interventions and strategies to prevent, diagnose, treat and monitor health conditions. Its
purpose is to inform patients, providers and decision-makers about which interventions are
most effective for patients under specific circumstances [17]. CER may employ
observational or clinical trial methodologies to compare strategies for care available in
typical healthcare settings, provided by typical healthcare providers, addressing a
comprehensive array of health-related outcomes. In general, outcomes are favored to be
patient centered and the research should be conducted in ‘real world’ diverse and
representative patient populations. Translational research includes three stages: T1 is the
classic bench-to-bedside (or rather human) translation; T2 constitutes efficacy research and
clinical trials; and T3 is translational research into health delivery, effectiveness and
implementation that explores general medical practice [23]. Thus, CER methods have the
opportunity to evolve toward the translation of research findings that emerge from
traditional efficacy research, in which comparisons between alternatives (including no
treatment or placebo) are conducted in controlled clinical trials within narrowly selected
patient populations (i.e., those who are presupposed to benefit) and in resource-intensive
research settings in which interventions are administered by investigators and their research
staff. Comparative efficacy studies include research to evaluate the effects of interventions,
thus measuring outcomes related to underlying disease mechanisms or clinical changes to
the disease from interventions. In short, comparative efficacy studies are critical to
answering questions such as ‘Can this intervention work?’ and ‘How does this intervention
work?’ under ideal and carefully controlled research conditions, whereas comparative
effectiveness studies may address translational questions such as ‘Which interventions when
translated into practice result in care improvements and increase the likelihood of health
benefits?’ Ultimately, it is the efficacy research that leads to innovations and effectiveness
research that leads to practice change and improved health (Figure 1).
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A straightforward approach to CER would be to apply traditional efficacy methods such as
the strong research design of the RCT. However, not every important CER question can be
answered by large RCTs. Even pragmatic strategies that attempt to minimize investigator
control of interventions, reduce exclusions and maximize generalizability have limitations
due to resource availability, sufficient patients or sample size for enrollment, and lengthy
time needed for outcome evaluation and follow-up. As trial synthesis and meta-analysis
currently rely on evidence from randomized clinical trials, one can anticipate tension in how
to apply these methods to CER with sufficient representativeness and generalizability that
will require expanded intermediary study designs. New approaches to observational designs
should thus be part of the methodological development to realize the promise of CER and
translational science. Synergy of these approaches, such as large database development, with
health information technology mandates may create unique opportunities with a national
evolution to electronic medical records and interoperability. For COPD, novel opportunities
for translational and effectiveness methodologies may evolve to effectively and efficiently
evaluate CER questions and guide subsequent care innovation.
One example of this kind of research that can ultimately also help guide implementation and
care improvement can come from conducting CER within linked registries that have been
organized to monitor and guide quality of care [24,25]. By conducting translational and CER
research across linked registries for patients and providers in real world conditions,
researchers and policymakers can explore CER across a wide representative sample of US
hospitals and monitor effects of healthcare policy and care improvement efforts serially over
time. Methods that employ sophisticated modeling techniques to control for confounding
and selection bias have evolved and the large samples reduce opportunities for error [26–
32]. In addition, subgroups such as those in racial and ethnic minorities, the
socioeconomically disadvantaged and those with multimorbid conditions can be assessed for
differences in responses, risks and benefits.
In some circumstances, confounding and selection bias cannot be definitively excluded in
observational designs and thus large randomized clinical trials will be needed to assess the
comparative effectiveness of some treatment alternatives. However, even in these trials,
observational studies can guide the development and design of pragmatic RCTs by
providing essential preliminary data on relevant comparators, outcomes and estimations of
sample size. Even when a definitive RCT answers a particular CER question, databases and
registries will be beneficial for studying implementation and practice change. Such
resources will additionally enable ongoing surveillance and quality monitoring across
patient-focused outcomes that can further guide practice changes. Large, representative,
multisite registries, preferably enhanced in the future with clinical information derived from
increased use of electronic medical records, may provide the necessary data monitoring of
the effects of practice change, including assessing for harm in real world settings. With
sustained funding, registry-conducted CER could document care delivery and provide
quality measurement that can assist ongoing care enhancement and compliment
experimental design by informing future clinical trials.
Mixed methods and quasi-experimental designs should also be considered as part of the
comprehensive approach to CER in COPD [26–32]. Research in real world settings may not
always have the luxury of random assignment or it may be difficult to devise a control group
because of ethical objections to withholding an intervention or components of the
intervention from one of the study groups. In addition, the researcher may not have the level
of control of the delivery of the intervention in the real world setting that can be found in an
experimental setting. Quasi-experimental designs can be a strong alternative to randomized
clinical trials when research is conducted in real world settings. The trade-off involved with
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conducting research in the sometimes difficult real world setting is increased external
validity and generalizability to other real world clinical settings.
Quasi-experimental designs, such as the regression discontinuity design, have been shown,
when analyzed correctly, to lead to unbiased estimates of the difference between groups
[26–28,31]. In this design, assignment to groups is based on some continuous variable;
individuals who exceed some threshold are assigned to the experimental group and those
that do not are assigned to the control group. This type of design mimics what happens in
the clinical setting, where, for example, patients are prescribed blood pressure medicine only
if their blood pressure exceeds safe limits. Interrupted time series and nonequivalent control
group designs are other useful approaches in community-based research, in which outcomes
are followed over time [30]. While not as strong as the regression discontinuity or
interrupted time series designs, the nonequivalent control group design can be strengthened
through the use of certain design elements and statistical analyses [27,31,32]. In this design,
naturally occurring groups of participants are compared. The groups could be, for example,
patients treated at different clinics or treated by different healthcare teams.
Given the impracticality of testing every clinical intervention in comparative pragmatic
trials, we advocate expanding methodology that includes the use of linked registries, serially
performed rigorous observational effectiveness analyses and quasi-experimental designs for
CER in COPD. To further ensure that the benefits promised by CER (whether by
observational, RCT or quasi-experimental design) are indeed realized, we would further
recommend follow-up studies to evaluate time trends in quality metrics, health outcomes to
monitor for possible harms and subgroup variations, and costs analyses to be considered as
components of implementation.
Exemplary CER work: treatment of acute exacerbation of COPD
A recent example of CER in COPD comes from the work by Lindenauer and colleagues
published in 2010 [11]. Using a large administrative data set from linked cohorts across the
premier health-care system, the investigators compared non-intensive care unit-hospitalized
patients receiving intravenous or oral steroids for acute COPD exacerbations. The use of
steroids is one of the few guideline-recommended care interventions with efficacy research
support [6–8,105,106]. The guidelines advocate the use of systemic cortico-steroids for
hospitalized COPD exacerbations and generally suggest oral prednisone equivalents of 30–
40 mg daily if tolerated, or if it is unable to be used orally, then to use equivalent
intravenous doses. However, the best efficacy data for steroids come from the seminal paper
by Neiwoehner and colleagues in 1999 who conducted a three-arm RCT where all patients
initially received 125-mg intravenous methylprednisolone every 6 h for 72 h followed by
different oral prednisone daily tapers [33]. The guideline recommendations are influenced
by the increased side effects associated with higher corticosteroid dosages.
One of the key findings of the Lindenauer et al. study was the documentation of care
delivery that differs greatly from guidelines, perhaps being significantly influenced by the
seminal efficacy study [11,33]. Lindenauer and colleagues identified intravenous doses that
ranged from 120 to 800 mg/day prednisone equivalents in the vast majority of patients with
those that did receive oral dose receiving 20–80 mg/day prednisone equivalents.
The investigators went on to develop a composite patient-centered outcome based on
treatment failure, the need for mechanical ventilation after hospital day 2, readmission
within 30 days and inpatient mortality. The study’s major finding was that there was no
worse outcome with low-dose oral steroids compared with high-dose intravenous delivery.
The investigators found a trend to better outcomes with low-dose oral steroids with an
unadjusted treatment failure odd ratio of 0.91 (95% CI: 0.83–1.00). They further
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demonstrated rigorous CER observational methods to adjust for sources of bias, including
propensity score and covariate adjustment, matched sample unbalanced covariate
adjustment, and dose effect modeling assuming a 10% increase in the proportion of oral
steroid use in hospitals.
The accompanying editorial from two CONCERT investigators noted that there are two
“options for moving forward. One approach would be to conduct a large-scale, pragmatic,
noninferiority clinical trial [requiring] 30,000 [to 120,000] patients” [25]. This calculation
came from the effect sizes in the Lindenauer paper demonstrating the utility of observational
studies for planning of subsequent RCTs. Alternatively, clinicians and healthcare systems
could “advocate for translating these research findings into clinical practice now and for
developing implementation and dissemination campaigns to facilitate uptake, including the
development and testing of quality metrics.” Well noted is that “caution should be exercised
when advocating a change in clinical practice based on observational research” alone. But
here indeed lies another opportunity for CER within linked registries, “enabling ongoing
surveillance of care quality and patient outcomes [and] can be used to track changes in
practice, patient adherence, as well as benefits and harms in real world settings.”
Thus, observational data repositories that are refreshed over time with sustained funding
could further assess any potential harm from practice changes as well as explore benefit in
subgroups, including those typically under-represented in efficacy research (e.g., those with
multiple comorbid conditions or race/ethnic minorities). Data sources could further be used
to document the quality of care delivery and provide useful quality measurement to track
and assist efforts to enhance care. Such monitoring over time could provide further CER
evidence that improvements in health and outcomes occur with research translation and
implementation [25].
Consortium for CER in COPD: CONCERT
In response to the emerging CER landscape and prior identification of the need for better
research translation, implementation and outcome analyses in COPD, we have established a
consortium for COPD research with an explicit focus on CER. CONCERT is an
interdisciplinary and multi-institutional team of investigators dedicated to improving the
outcomes of patients with COPD through the development of effective methods to translate
biomedical knowledge into routine practice [108]. With research funding support from
AHRQ and the National Heart, Lung, and Blood Institute (NHLBI), CONCERT has begun
working in the CER arena in COPD, including successfully engaging a national group of
stakeholder organizations to identify and prioritize a translational research agenda in acute
and chronic COPD care.
Published research by CONCERT investigators has demonstrated that the care and outcomes
of patients with COPD vary substantially across the USA, and that many patients are not
benefiting from guideline-recommended therapies supported by efficacy research [4,13].
One potential contributor to such practice variation is the lack of data about the effectiveness
of treatment strategies in ‘real world’ clinical practice. We also surmise that gaps in health
services knowledge about how best to implement evidence-based care in diverse clinical
settings contribute to poor translation. Such gaps in effectiveness knowledge may lead to
limited healthcare decision-making amongst patients and clinicians. These factors and other
aspects, such as healthcare costs associated with the novel adoption of new and often more
expensive treatments, have been implicated as reasons for poor translation of clinical
efficacy data into best clinical practices and have stimulated the NIH to develop a COPD
Awareness Campaign [109]. On the basis of the emerging research paradigms, these
findings have increased interest in comparisons of existing interventions, including
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pharmacologic agents, devices, and strategies of care to improve outcomes and the
efficiency with which healthcare is delivered. Through a series of Consensus Conferences
(‘Setting effectiveness and translational research priorities to improve COPD care’) held in
2009 and 2010, CONCERT explored various topics and research questions amongst its
diverse transdisciplinary group.
CONCERT is a multi-institutional and interdisciplinary consortium of investigators at six
US medical centers (Baystate Medical Center, Kaiser Permanente Northwest and The Center
for Health Research, University of Chicago, University of Illinois at Chicago, University of
North Carolina at Chapel Hill, and University of Washington) with expertise in comparative
effectiveness, cost–effectiveness, epidemiology, pharmacoepidemiology, statistics, clinical
trials, performance measurement, quality improvement, behavioral psychology and multi-
center data coordination. Investigators within CONCERT also have clinical expertise in
hospital medicine, pulmonary medicine, critical care medicine and behavioral science, and
provide care to diverse patient populations with COPD in managed care and nonmanaged
care settings. The network engaged private, governmental and patient advocacy groups
through support from an R13 conference grant from the AHRQ (HS017894) to identify and
discuss research topics and questions in COPD. The uniqueness of the stakeholder group
includes its broad representation and extensive expertise of participants that spans insurers/
health plans, professional organizations, quality improvement organizations, government
and private research entities, and patient advocacy groups (Box 1). As part of the methods of
developing prioritized topics for CER in COPD, CONCERT worked with its workshop
participants who were solicited from its stakeholder groups and identified research questions
for consideration. The solicitation had the expressed objective of identifying real world
translational research questions and strategies to accelerate adoption and implementation of
interventions to improve COPD care. General topics in COPD that were considered are
summarized in Box 2–5.
Box 1
Stakeholder groups who participated in CONCERT Consensus
Conferences
• Agency of Healthcare Research and Quality
• Alpha 1 Foundation
• American Academy of Family Physicians
• American Academy of Sleep Medicine
• American Association of Cardiovascular and Pulmonary Rehabilitation
• American Association of Critical Care Nurses
• American Association of Respiratory Care
• American College of Chest Physicians
• American College of Emergency Physicians
• American College of Physicians
• American Geriatrics Society
• American Health Quality Association
• American Public Health Association
• Association of Pulmonary and Critical Care Program Directors
• Baystate Health
• Blue Cross/Blue Shield
• Boehringer Ingelheim
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• Canadian Association of Emergency Physicians Research Consortium
• Centers for Medicaid and Medicare Services
• COPD Foundation
• Health Maintenance Organization Research Network
• Kaiser Permanente Northwest
• National Association of Social Workers
• National Heart Lung Blood Institute
• National Institute of Nursing Research
• National Institute on Aging
• National Patient Safety Foundation
• North American Primary Care Research Group
• Ohio State University
• Olmstead Medical Center
• Pittsburgh Regional Health Initiative
• Respiratory Health Association of Metropolitan Chicago
• Respiratory Nursing Society
• Society for Academic Emergency Medicine
• Society of Critical Care Medicine
• Society for General Internal Medicine
• Society of Hospital Medicine
• Society for Medical Decision Making
• The Center for Health Research, Kaiser Permanente
• The Joint Commission
• University of Chicago
• University of Illinois
• University of North Carolina
• Wellpoint
COPD: Chronic obstructive pulmonary disease.
Box 2
Research topics in chronic obstructive pulmonary disease care
coordination
• Management of COPD in the presence of comorbidity
• Pulmonary rehabilitation (as a model for care coordination)
• Impact of depression and mental health management
• Measurement of quality of care coordination
• Quality of care coordination
• Comprehensive COPD patient education
• Cost–effectiveness of care coordination
• Case management
• Developing a tool for risk stratification of patients with COPD
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• Patient-centered medical home
• Scheduled multidisciplinary team consultation
COPD: Chronic obstructive pulmonary disease.
Box 3
Research topics in chronic obstructive pulmonary disease care
• Spirometry for diagnosis and treatment
• Pulmonary rehabilitation (effectiveness of care)
• Effectiveness of COPD care and guideline translation
• Home care
• Development of performance measures
• Oxygen therapy
• Palliation of symptoms
• Pharmaceutical treatment
• Smoking cessation
COPD: Chronic obstructive pulmonary disease.
Box 4
Research topics in acute chronic obstructive pulmonary disease care
• Implementation of AE-COPD
• Comorbid conditions in the acute setting
• Effectiveness and implementation of NIV in acute respiratory failure
• Role of antibiotics in acute exacerbations
• Quality of care assessment
• Dyspnea in COPD
• Oxygen therapy postexacerbation
• Interventions for acute airway obstruction
AE-COPD: Acute exacerbations of chronic obstructive pulmonary disease; COPD: Chronic obstructive
pulmonary disease; NIV: Noninvasive ventilation.
Box 5
Research topics in transitions in chronic obstructive pulmonary disease
care
• Integrated healthcare strategies during transitions in COPD care
• Multimorbidity and transitions in COPD care
• Patient and family activation during transitions in COPD care
• End of life/palliative care and transitions in COPD care
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• Psychosocial barriers during transitions in COPD care
• Modeling effects of interventions in COPD status
COPD: Chronic obstructive pulmonary disease.
In a series of two conferences coinciding with the American Thoracic Society meetings
(‘Setting effectiveness and translational research priorities to improve COPD care’) the
CONCERT consortium worked to develop a research agenda across four areas:
• Chronic COPD care
• COPD care coordination
• Acute COPD care
• Transitions in COPD care
Advancing the methodology for consensus building amongst stakeholders in COPD,
CONCERT adapted modified Delphi techniques for ranking and the use of analytical
hierarchy processes for developing prioritized agendas [34–37]. A separate report
summarizing the results of the Consensus Conferences is in development.
In addition, with funding from the NHLBI (RC2 HL101618), CONCERT has also designed
and developed a comprehensive data repository for patients with evidence of obstructive
lung disease across its six sites called the COPD Data Hub. The intent of this Data Hub is to
support novel CER studies in diverse COPD patient populations that span managed care and
non-managed care settings linked to the research agenda developed during the CONCERT
Consensus Conferences. In this respect, CONCERT is attempting to respond to the DHHS
definition for CER, which emphasizes the need for stakeholder input in the conduct of CER
studies. The COPD Data Hub links administrative and electronic sources of clinical data
across the six CONCERT clinical centers and if successfully maintained with sustaining
funding will provide longitudinal data on care practices and health outcomes across diverse,
real world, healthcare settings. The COPD Data Hub was designed to be flexible and
incorporate data from varied healthcare settings that include university-affiliated medical
centers, a community medical center, a health maintenance organization and a government-
operated veteran medical center. Preliminary data from 2006 to 2008 (pending 2009–2010
data collection) includes 146,240 unique patients of whom 58.3% were female at nonveteran
sites; 68.4% were Caucasians and 14.3% African–American, and the average patient age
was 61.8 years (standard deviation: 13.5) [38,39]. These findings suggest that the COPD
Data Hub will include a substantially greater diversity of patients (e.g., higher proportion of
women and greater diversity by race) than has been typically possible in recently published
large-scale clinical trials of efficacy [9,10]. The COPD Data Hub infrastructure will
facilitate the development of appropriately designed and ‘shovel-ready’ observational CER
studies. Furthermore, CONCERT has enriched the COPD Data Hub by collecting additional
detailed clinical and questionnaire information on a sample of 1200 patients selected from
the COPD Data Hub. With added data of baseline spirometry, 6-min walk distance and
quality of life metrics, the Network can further validate and leverage the usefulness of the
larger COPD Data Hub by linking it to disease severity, functional status and various
patient-centered outcomes. In addition, recruited individuals can serve to accelerate
enrollment into subsequent CER prospective studies. Using the Data Hub, CONCERT has
recently conducted a preliminary analysis of recommended care components that might be
used to comprise a quality of care bundle for hospitalized acute exacerbations of COPD.
Targeting priorities from our Consensus Conferences, we explored interventions to improve
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care delivery. Drawing from clinical practice guidelines, we identified components of
recommended care such as the use of bronchodilators, supple mental oxygen, noninvasive
positive pressure ventilation and corticosteroids. We then used a cross-sectional design
across a random sample of acute COPD hospitalizations in the year 2008 from our Data
Hub. Using existing data in the COPD Data Hub supplemented with chart abstraction, we
explored how often we could find evidence for care delivery for the recommended
components of care for hospitalized COPD acute exacerbation [39]. From 242 unique
patients across our six sites, we identified variation and low delivery of all components of a
possible care bundle (Figure 2). These findings supported the development of a multisite
research application to improve the care of hospitalized COPD acute exacerbation.
Conclusion
In general, CER in COPD will require the development of infrastructures to support
collaboration between researchers and the stakeholders who generate, disseminate and use
new knowledge. Methodologies need to evolve to both prioritize research questions with
stakeholder input and to conduct collaborative CER studies of high potential value.
Stakeholder representation should routinely include patients, clinicians, professional
organizations, payers, policymakers, regulators, funding agencies and researchers. Given the
impracticality of testing every clinical intervention in comparative pragmatic trials for CER
in COPD, we advocate expanding methodologies to include the use of observational
databases with serially performed effectiveness analyses and quasi-experimental designs. To
further ensure that the benefits promised by CER are indeed realized, we would further
recommend follow-up studies in linked registries to evaluate trends over time in quality
metrics and health outcomes. Such monitoring will further allow monitoring for possible
harms, analyses within subgroups or in those with comorbidities, and explorations of cost as
a component of implementation research.
Future perspective
COPD is an increasingly prevalent and morbid disease worldwide with considerable
consequences in human suffering, disability and economic cost. Over the next decade,
substantial work will be needed to understand which therapies should be used in which
patients and how efficiently they decrease symptoms, reduce hospitalizations or
exacerbations, and potentially slow disease progression. For CER to impact individuals in
real world populations with multimorbid illnesses, methodological techniques will need to
evolve from the current reliance on placebo-controlled efficacy studies in highly selected
populations to pragmatic and observational studies with rigorous study design. Registries
and multisite cross-institutional databases are likely to play important roles in guiding the
translation of efficacy research-supported COPD therapies and allowing and supporting
quality measurement and improvement in the treatment of COPD. Serial real-time
assessments in such registries will allow longitudinal follow-up and enable exploration into
how healthcare delivery and implementation of changes based on CER actually effect
individuals and subpopulations. This is an exciting time for research across diseases such as
COPD and holds great promise for improving health if future funding adequately sustains
the evolving infrastructures and political pressures do not undermine rational data gathering
and transparent analysis and dissemination.
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• Chronic obstructive pulmonary disease (COPD) affects millions worldwide and
is the third leading cause of death in the USA, and results in significant
morbidity and cost.
• The Institute of Medicine defines comparative effectiveness research (CER) as
“the generation and synthesis of evidence that compares the benefits and harms
of alternative methods to prevent, diagnose, treat and monitor a clinical
condition or to improve the delivery of care. The purpose of CER is to assist
consumers, clinicians, purchasers and policymakers to make informed decisions
that will improve healthcare at both the individual and population levels.”
• The USA 2010 Patient Protection and Affordable Care legislation established
the Patient-Centered Outcomes Research Institute that has been charged with
establishing a functional approach and practical strategies to develop and
organize the infrastructure for prioritizing and conducting CER.
• CER includes observational or clinical trial methodologies to compare strategies
for care available in typical healthcare settings, provided by typical healthcare
providers, addressing a comprehensive array of health-related outcomes.
• New approaches to randomized trials, observational studies and evidence
synthesis methodology will be needed to realize the promise of CER and
translational science in COPD and across other diseases.
• Given the impracticality of testing every clinical intervention in large
randomized comparative trials, CER will benefit from expanding observational
methodology that includes the use of linked registries with serially performed
analyses and quasi-experimental designs for CER in COPD.
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Figure 1. Translational research model
Efficacy (T2) leads to innovation while effectiveness and implementation (T3) lead to health
improvement.
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Figure 2. Processes of care and summary measures at each CONCERT site
CONCERT: Chronic obstructive pulmonary disease Outcomes-based Network for Clinical
Effectiveness and Research Translation.
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